Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche, Bristol On The Defensive After Merck's Lung Cancer Wins At ASCO

Executive Summary

With Merck's Keytruda on top of the world and setting the standard for PD-1/L1 lung cancer data, Roche and Bristol defended the programs for their competing Tecentriq and Opdivo during ASCO investor events.

Advertisement

Related Content

Amid PD-1 Uncertainty, Bristol Under Pressure For M&A Activity
Pharma Q3 Results Preview: Merck Vs. Bristol In IO Showdown
IMpower132 Casts More Doubt On Roche's Tecentriq In First-Line NSCLC
Bristol's Opdivo Enjoys IO First-Mover Advantage In Small Cell Lung Cancer
First-Line Chemo Combo Data Help Merck's Keytruda Power Past Opdivo
Pharma Q2 Results Preview: AstraZeneca, Roche, Merck And BMS
Merck's Stellar Keytruda Squamous Lung Cancer Data Refute Naysayers
Roche's IMpower150 Gets AACR Applause But Merck's KEYNOTE-189 Big Winner
Merck's Keytruda Enjoys Clean Sweep In Lung Cancer, At Bristol's Expense
Bristol's Opdivo/Yervoy Bid Will Show Whether Tumor Mutation Burden Is Ready For Prime Time

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123208

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel